allopurinol Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
124 315-30-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zyloprim
  • allopurinol
  • tautomeric mixture of 1H-pyrazolo[3,4-d]pyrimidin-4-ol and 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
  • allopurinol sodium
A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.
  • Molecular weight: 136.11
  • Formula: C5H4N4O
  • CLOGP: 0.63
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 74.69
  • ALOGS: -0.79
  • ROTB: 0

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

Approvals:

DateAgencyCompanyOrphan
Aug. 19, 1966 FDA PROMETHEUS LABS

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 4841.03 40.09 896 3839 6999 3374125
Stevens-Johnson syndrome 1346.05 40.09 305 4430 6467 3374657
Toxic epidermal necrolysis 1236.52 40.09 265 4470 4280 3376844
Acute kidney injury 1073.67 40.09 396 4339 49287 3331837
Pyrexia 678.20 40.09 330 4405 80785 3300339
Rash 633.35 40.09 302 4433 70519 3310605
Eosinophilia 597.68 40.09 149 4586 4724 3376400
Rash maculo-papular 512.71 40.09 137 4598 5730 3375394
Renal failure 458.15 40.09 192 4543 32748 3348376
Dermatitis exfoliative 371.84 40.09 91 4644 2652 3378472
Thrombocytopenia 333.44 40.09 157 4578 35111 3346013
Pruritus 325.43 40.09 169 4566 46664 3334460
Renal impairment 323.93 40.09 127 4608 18134 3362990
Pancytopenia 306.26 40.09 123 4612 18697 3362427
Drug interaction 305.45 40.09 162 4573 46650 3334474
Skin exfoliation 299.38 40.09 97 4638 7940 3373184
Hepatitis 262.85 40.09 92 4643 9533 3371591
Drug eruption 262.72 40.09 79 4656 5046 3376078
Erythema multiforme 260.47 40.09 71 4664 3182 3377942
Toxic skin eruption 246.67 40.09 67 4668 2961 3378163
Rhabdomyolysis 235.82 40.09 97 4638 15632 3365492
Erythema 231.83 40.09 115 4620 28695 3352429
Gout 230.90 40.09 65 4670 3282 3377842
Dilatation intrahepatic duct acquired 227.18 40.09 36 4699 80 3381044
Agranulocytosis 221.90 40.09 70 4665 5242 3375882
Alanine aminotransferase increased 219.17 40.09 104 4631 23536 3357588
Sepsis 204.96 40.09 110 4625 32263 3348861
Anaemia 202.61 40.09 131 4604 54202 3326922
Rash erythematous 201.66 40.09 72 4663 7890 3373234
Hyperkalaemia 201.56 40.09 79 4656 11215 3369909
Drug hypersensitivity 197.66 40.09 111 4624 35569 3345555
Human herpesvirus 6 infection 192.03 40.09 40 4695 545 3380579
Diarrhoea 187.21 40.09 162 4573 104186 3276938
Blood creatinine increased 187.03 40.09 91 4644 21727 3359397
Hepatotoxicity 186.63 40.09 62 4673 5469 3375655
Multiple organ dysfunction syndrome 182.95 40.09 79 4656 14331 3366793
Hyperuricaemia 182.15 40.09 45 4690 1358 3379766
Liver disorder 177.08 40.09 70 4665 10153 3370971
Blister 173.26 40.09 66 4669 8668 3372456
Cholestasis 168.85 40.09 57 4678 5280 3375844
Eczema 166.59 40.09 53 4682 4073 3377051
Tubulointerstitial nephritis 163.40 40.09 53 4682 4333 3376791
Hypotension 159.33 40.09 109 4626 49405 3331719
Rash generalised 159.04 40.09 64 4671 9718 3371406
Face oedema 158.62 40.09 54 4681 5130 3375994
International normalised ratio increased 156.12 40.09 71 4664 14544 3366580
Aspartate aminotransferase increased 148.37 40.09 77 4658 21036 3360088
Leukopenia 147.66 40.09 70 4665 15753 3365371
Oedema peripheral 145.72 40.09 90 4645 34271 3346853
Septic shock 145.48 40.09 64 4671 12120 3369004
Actinic keratosis 142.58 40.09 33 4702 748 3380376
Chronic kidney disease 140.17 40.09 52 4683 6340 3374784
Interstitial lung disease 140.00 40.09 65 4670 13951 3367173
Lymphadenopathy 139.73 40.09 55 4680 7877 3373247
Purpura 136.36 40.09 42 4693 2898 3378226
Completed suicide 133.17 40.09 82 4653 31032 3350092
Liver injury 132.46 40.09 43 4692 3521 3377603
Shock 132.44 40.09 51 4684 6886 3374238
Metabolic acidosis 124.17 40.09 52 4683 8726 3372398
Dehydration 122.34 40.09 80 4655 33569 3347555
Hepatic function abnormal 121.30 40.09 55 4680 11172 3369952
Conjunctivitis 121.20 40.09 38 4697 2780 3378344
Rash pruritic 118.70 40.09 51 4684 9113 3372011
Drug-induced liver injury 117.26 40.09 43 4692 5070 3376054
Dyspnoea 116.15 40.09 124 4611 102810 3278314
Neutropenia 115.60 40.09 77 4658 33309 3347815
Haemoglobin decreased 107.59 40.09 71 4664 30223 3350901
Tumour lysis syndrome 106.98 40.09 33 4702 2286 3378838
Angioedema 105.67 40.09 55 4680 15080 3366044
Cardiac failure 104.23 40.09 60 4675 20045 3361079
Dermatitis 103.26 40.09 35 4700 3275 3377849
Pneumonia 101.93 40.09 97 4638 70046 3311078
Transaminases increased 101.80 40.09 42 4693 6782 3374342
Oedema 101.50 40.09 53 4682 14627 3366497
Leukocytosis 101.13 40.09 40 4695 5793 3375331
General physical health deterioration 100.26 40.09 59 4676 20530 3360594
Acute lymphocytic leukaemia recurrent 99.89 40.09 22 4713 395 3380729
Hypersensitivity 98.11 40.09 65 4670 27835 3353289
Aplasia pure red cell 97.23 40.09 28 4707 1529 3379595
Blood alkaline phosphatase increased 96.28 40.09 46 4689 10507 3370617
Blood urea increased 94.37 40.09 41 4694 7519 3373605
Hepatocellular injury 93.56 40.09 35 4700 4360 3376764
Malaise 92.51 40.09 89 4646 65088 3316036
Respiratory failure 91.39 40.09 58 4677 23083 3358041
Hepatic failure 89.83 40.09 44 4691 10608 3370516
Skin lesion 89.80 40.09 36 4699 5397 3375727
Lactic acidosis 88.18 40.09 39 4696 7461 3373663
Liver function test abnormal 87.52 40.09 46 4689 12855 3368269
Venoocclusive liver disease 87.31 40.09 25 4710 1337 3379787
Rash morbilliform 86.87 40.09 22 4713 734 3380390
Bone marrow failure 86.68 40.09 40 4695 8447 3372677
Asthenia 86.33 40.09 86 4649 65579 3315545
Vomiting 85.58 40.09 99 4636 89432 3291692
Acute generalised exanthematous pustulosis 84.83 40.09 27 4708 2072 3379052
Hepatic enzyme increased 82.37 40.09 45 4690 13580 3367544
Platelet count decreased 82.34 40.09 58 4677 27410 3353714
White blood cell count increased 82.32 40.09 44 4691 12716 3368408
Decreased appetite 77.15 40.09 66 4669 41424 3339700
Jaundice 77.09 40.09 39 4696 10068 3371056
Vasculitis 76.22 40.09 28 4707 3313 3377811
Toxicity to various agents 75.82 40.09 69 4666 46985 3334139
Gastrointestinal haemorrhage 74.28 40.09 52 4683 24322 3356802
Precancerous skin lesion 73.52 40.09 16 4719 271 3380853
Blood uric acid increased 72.45 40.09 22 4713 1444 3379680
Rash pustular 71.73 40.09 24 4711 2156 3378968
Premature baby 70.38 40.09 33 4702 7220 3373904
Hypersensitivity vasculitis 69.20 40.09 23 4712 2024 3379100
Hyperpyrexia 68.77 40.09 19 4716 891 3380233
Dermatitis bullous 67.92 40.09 23 4712 2143 3378981
Acute hepatic failure 67.02 40.09 27 4708 4096 3377028
Atrial fibrillation 65.86 40.09 48 4687 23893 3357231
Stomatitis 65.75 40.09 37 4698 11815 3369309
Haemodialysis 64.78 40.09 27 4708 4465 3376659
Extravasation blood 64.17 40.09 11 4724 46 3381078
Wheezing 63.68 40.09 32 4703 8139 3372985
Aplastic anaemia 63.61 40.09 20 4715 1474 3379650
Renal tubular necrosis 63.41 40.09 24 4711 3084 3378040
Confusional state 61.72 40.09 56 4679 37942 3343182
Tachycardia 60.11 40.09 45 4690 23326 3357798
Splenomegaly 59.65 40.09 23 4712 3108 3378016
Disseminated intravascular coagulation 59.43 40.09 28 4707 6189 3374935
Lichenoid keratosis 58.72 40.09 15 4720 518 3380606
Nausea 58.47 40.09 100 4635 129545 3251579
Blood lactate dehydrogenase increased 58.32 40.09 28 4707 6452 3374672
Mouth ulceration 58.30 40.09 25 4710 4435 3376689
Condition aggravated 58.26 40.09 55 4680 39178 3341946
Blood creatine phosphokinase increased 57.35 40.09 35 4700 12978 3368146
Histiocytosis haematophagic 57.15 40.09 20 4715 2056 3379068
Swelling face 56.27 40.09 33 4702 11383 3369741
Blood bilirubin increased 56.11 40.09 32 4703 10477 3370647
Parakeratosis 56.08 40.09 11 4724 108 3381016
Mucosal inflammation 55.64 40.09 29 4706 7954 3373170
Melaena 55.11 40.09 28 4707 7284 3373840
Febrile neutropenia 54.35 40.09 39 4696 18936 3362188
Skin cancer 53.55 40.09 19 4716 2033 3379091
Lymphocyte morphology abnormal 52.92 40.09 12 4723 247 3380877
Rash macular 52.62 40.09 23 4712 4271 3376853
Sinoatrial block 52.34 40.09 12 4723 260 3380864
Neutropenic sepsis 51.98 40.09 20 4715 2686 3378438
Microphthalmos 51.67 40.09 10 4725 91 3381033
Serum ferritin increased 51.57 40.09 17 4718 1457 3379667
Venoocclusive disease 51.39 40.09 14 4721 622 3380502
Copper deficiency 51.37 40.09 8 4727 15 3381109
Vasculitis cerebral 51.25 40.09 12 4723 286 3380838
White blood cell count decreased 51.10 40.09 42 4693 24905 3356219
Mucous membrane disorder 50.59 40.09 14 4721 660 3380464
Skin oedema 50.17 40.09 12 4723 314 3380810
Pleural effusion 50.16 40.09 37 4698 18742 3362382
Oral herpes 49.23 40.09 18 4717 2099 3379025
Hypereosinophilic syndrome 48.92 40.09 10 4725 123 3381001
Cytomegalovirus infection 48.37 40.09 22 4713 4485 3376639
Interstitial granulomatous dermatitis 47.99 40.09 9 4726 68 3381056
Tachypnoea 46.69 40.09 20 4715 3536 3377588
Gamma-glutamyltransferase increased 46.60 40.09 27 4708 9101 3372023
Hyponatraemia 46.41 40.09 35 4700 18324 3362800
Mucosal erosion 46.13 40.09 11 4724 284 3380840
HLA marker study positive 46.01 40.09 8 4727 37 3381087
C-reactive protein increased 45.91 40.09 27 4708 9356 3371768
Conjunctival hyperaemia 45.55 40.09 14 4721 956 3380168
Skin reaction 45.32 40.09 18 4717 2630 3378494
Haemolytic anaemia 45.30 40.09 19 4716 3190 3377934
Hypovolaemia 45.09 40.09 17 4718 2159 3378965
Bradycardia 44.86 40.09 33 4702 16636 3364488
Patent ductus arteriosus 44.77 40.09 15 4720 1352 3379772
Lung disorder 44.52 40.09 26 4709 8891 3372233
Epistaxis 44.38 40.09 31 4704 14420 3366704
Cryptorchism 44.30 40.09 11 4724 338 3380786
Acanthosis 44.23 40.09 9 4726 108 3381016
Urticaria 44.01 40.09 41 4694 28686 3352438
Myalgia 43.87 40.09 43 4692 32032 3349092
Dialysis 43.46 40.09 20 4715 4189 3376935
Fatigue 43.45 40.09 79 4656 107161 3273963
Petechiae 43.29 40.09 18 4717 2956 3378168
Anti-erythropoietin antibody negative 43.16 40.09 7 4728 19 3381105
Pancreatitis acute 42.86 40.09 23 4712 6685 3374439
Weight decreased 42.69 40.09 47 4688 40064 3341060
Hyperglycaemia 42.56 40.09 25 4710 8643 3372481
Pulmonary oedema 42.40 40.09 28 4707 11883 3369241
Maternal drugs affecting foetus 42.35 40.09 19 4716 3752 3377372
Foetal exposure during pregnancy 42.33 40.09 31 4704 15520 3365604
Dysphagia 42.16 40.09 34 4701 19617 3361507
Generalised erythema 41.60 40.09 16 4719 2145 3378979
Cholecystitis 41.38 40.09 18 4717 3303 3377821
Neutrophilic dermatosis 41.02 40.09 8 4727 76 3381048
Respiratory distress 40.67 40.09 24 4711 8364 3372760
Peritonitis 40.35 40.09 20 4715 4935 3376189
Haematocrit decreased 40.27 40.09 23 4712 7544 3373580
Lower respiratory tract infection 40.20 40.09 22 4713 6647 3374477

Pharmacologic Action:

SourceCodeDescription
ATC M04AA01 MUSCULO-SKELETAL SYSTEM
ANTIGOUT PREPARATIONS
ANTIGOUT PREPARATIONS
Preparations inhibiting uric acid production
ATC M04AA51 MUSCULO-SKELETAL SYSTEM
ANTIGOUT PREPARATIONS
ANTIGOUT PREPARATIONS
Preparations inhibiting uric acid production
CHEBI has role CHEBI:35845 gout suppressant
MeSH PA D000963 Antimetabolites
MeSH PA D000975 Antioxidants
MeSH PA D018501 Antirheumatic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D016166 Free Radical Scavengers
MeSH PA D006074 Gout Suppressants
MeSH PA D009676 Noxae
FDA EPC N0000175698 Xanthine Oxidase Inhibitor
FDA MoA N0000000206 Xanthine Oxidase Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hyperuricemia indication 35885006 DOID:1920
Articular gout indication 48440001 DOID:13189
Gout indication 90560007 DOID:13189
Uric acid renal calculus indication 274401005
Calcium renal calculus indication 427649000
Uric Acid Nephropathy Gout indication
Recurrent Calcium Renal Calculi indication
Chemotherapy-Induced Hyperuricemia indication
Deficiency of adenine phosphoribosyltransferase off-label use 124274002 DOID:0060350
Deficiency of ribose-phosphate pyrophosphokinase off-label use 124343001
Neonatal Phosphoribosylpyrophosphate Synthetase Superactivity off-label use
Dehydration contraindication 34095006
Chronic heart failure contraindication 48447003
Hypersensitivity angiitis contraindication 60555002 DOID:9809
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.52 acidic
pKa2 9.43 acidic
pKa3 1.45 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 8283369 Nov. 26, 2028 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 8357713 Nov. 26, 2028 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 8283369 Nov. 26, 2028 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 8357713 Nov. 26, 2028 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 8546437 April 29, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 8546437 April 29, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 8084483 Aug. 17, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 8084483 Aug. 17, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 9216179 Aug. 1, 2031 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 RX TABLET ORAL 9216179 Aug. 1, 2031 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Xanthine dehydrogenase/oxidase Enzyme INHIBITOR Ki 5.15 CHEMBL CHEMBL
Hypoxanthine-guanine phosphoribosyltransferase Enzyme WOMBAT-PK
Xanthine dehydrogenase/oxidase Enzyme Ki 6 CHEMBL
Xanthine dehydrogenase/oxidase Enzyme IC50 6.12 CHEMBL

External reference:

IDSource
CHEBI:40279 CHEBI
DB00437 DRUGBANK_ID
4017895 VUID
N0000146247 NUI
C0002144 UMLSCUI
6795 IUPHAR_LIGAND_ID
D00224 KEGG_DRUG
428673RC2Z UNII
17795-21-0 SECONDARY_CAS_RN
1731 INN_ID
1816 MMSL
519 RXNORM
25246002 SNOMEDCT_US
387135004 SNOMEDCT_US
4150 MMSL
d00023 MMSL
4017895 VANDF
N0000005830 NDFRT
N0000146247 NDFRT
001084 NDDF
8256 MMSL
CHEMBL1467 ChEMBL_ID
CHEMBL1200477 ChEMBL_ID
D000493 MESH_DESCRIPTOR_UI
2094 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Allopurinol sodium HUMAN PRESCRIPTION DRUG LABEL 1 0143-9533 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0378-0137 TABLET 100 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0378-0181 TABLET 300 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0591-5543 TABLET 100 mg ORAL NDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0591-5544 TABLET 300 mg ORAL NDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0603-2115 TABLET 100 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0603-2116 TABLET 300 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0615-1592 TABLET 100 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0615-1593 TABLET 300 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-6266 TABLET, COATED 100 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-6267 TABLET, COATED 300 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-6571 TABLET 100 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-6572 TABLET 300 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 10544-545 TABLET 100 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 10544-547 TABLET 300 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 10544-911 TABLET 300 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 16714-041 TABLET 100 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 16714-042 TABLET 300 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 16729-134 TABLET 100 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 16729-135 TABLET 300 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 21695-246 TABLET 300 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 21695-836 TABLET 100 mg ORAL ANDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 33261-597 TABLET 300 mg ORAL NDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 33261-810 TABLET 100 mg ORAL NDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 35356-856 TABLET 100 mg ORAL ANDA 12 sections
ALLOPURINOL HUMAN PRESCRIPTION DRUG LABEL 1 42549-500 TABLET 100 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 43063-079 TABLET 100 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 43063-774 TABLET 300 mg ORAL NDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 43063-793 TABLET 100 mg ORAL NDA 11 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 43353-088 TABLET 300 mg ORAL ANDA 12 sections